Charles River Laboratories International stock

CRL · NYSE · USD

Compare Charles River Laboratories International
$337.97Change from previous close: −0.83%Absolute change: −$2.84

Close · November 13, 2026

Price history

+99.73% over the period

1 year: from $169.21 (November 13, 2025) to $337.97 (November 13, 2026), +99.73%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$337.97
October 30, 2026$359.41
September 30, 2026$295.01
August 31, 2026$288.24
July 31, 2026$232.51
June 30, 2026$226.79
May 29, 2026$180.71
April 30, 2026$166.97
March 31, 2026$172.50
February 27, 2026$178.49
January 30, 2026$210.48
December 31, 2025$199.48
November 28, 2025$178.14
November 13, 2025$169.21

At a glance

  • The company

    Provides drug discovery, safety testing and research models, plus contract manufacturing services for pharma and biotech

  • Latest results

    Quarter to September 30, 2026 · EPS $3.09 (estimate $2.97)

TickerLandia's take on Charles River Laboratories International

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$146.20
52-wk high$379.63

−10.97% from the 52-week high

Analysts · 17 analysts

Average target$350.57+3.73% vs. price

Buy 14 · Hold 2 · Sell 1 · Buy

TickerLandia Fingerprint: Charles River Laboratories International

Compared with similar companies: very strong momentum and very low earnings stability.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Charles River Laboratories International is pricier than similar companies

Charles River Laboratories International's P/E (trailing 12 months): 367.4, +873% against the median of a group of 9 similar companies (37.7).

Compared with 9 similar companies

Charles River Laboratories International's metrics compared with similar companies
MetricCharles River Laboratories InternationalPosition in the groupBand
P/E (trailing 12 months)367.4High
Forward P/E26.1Middle
Operating margin14.3%Middle
ROE1.3%Low
Debt/equity0.87High

Grey band: the middle half of the group; tick: the median; dot: Charles River Laboratories International. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$982.73M

Latest quarter · Q3 2026

Net income

$333.07M

Latest quarter · Q3 2026

Quarterly net margin

33.9%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$16.19B
P/E
367.4
EPS
$0.92
Volume
823.14K
Daily trading
€403.88M
Dividend yield
0.00%

How Charles River Laboratories International is changing

All results
  • Revenue grew 6.5% a year on average over the last 5 years

  • Operating margin fell from 16.4% to 0.6%

  • Profitable in 4 of 5 fiscal years

Returns

Charles River Laboratories International returns

$1,000 invested in Charles River Laboratories International 5 years ago, on November 15, 2021, would be worth $879 today: −12.11% in total, −2.55% per year. This is the price return only: dividends are excluded.

PeriodCharles River Laboratories InternationalS&P 500$1,000 becomes
1 month+13.03%−3.12%$1,130
6 months+107.53%+1.58%$2,075
Year to date+69.43%+10.46%$1,694
1 year+99.73%+12.23%$1,997
3 years+98.77%+71.41%$1,988
5 years−12.11%+61.48%$879
10 years+350.27%+249.40%$4,503

Over the last 6 months it has done better than 99% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Charles River Laboratories International: technical analysis

Charles River Laboratories International is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 26.3% below its all-time closing high ($458.30, September 24, 2021).

Trend
Upward
RSI (14 sessions)
52
Between 30 and 70
vs 200-session average
+48.42%

Support and resistance

Price areas where Charles River Laboratories International has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$337.97
  3. Support$232.94−31.08%4 touches, last on July 10, 2026
  4. Support$215.89−36.12%2 touches, last on July 21, 2026
  5. Support$193.07−42.87%5 touches, last on June 10, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.29
Volatility (60 sessions, annualised)
48.1%
Largest fall in the last year
−33.88%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Charles River Laboratories International: seasonality

Average monthly price change over 27 years

+2.0%Jan+0.9%Feb+0.3%Mar−2.1%Apr+4.6%May+2.8%Jun+5.1%Jul+0.5%Aug+0.2%Sep−0.8%Oct−0.6%Nov+3.7%Dec

Over the last 27 years, the strongest month for Charles River Laboratories International has been July: +5.09% on average, positive in 17 years out of 27. The weakest has been April: −2.10% on average, positive in 10 years out of 26. November, the current month, has been positive in 13 years out of 26 (−0.60% on average).

Show chart data
MonthAverageMedianPositive years
January+1.97%+3.86%17 of 26
February+0.89%+0.88%16 of 26
March+0.27%+1.80%19 of 26
April−2.10%−1.66%10 of 26
May+4.61%+2.17%17 of 26
June+2.77%+0.81%14 of 26
July+5.09%+3.88%17 of 27
August+0.49%−0.64%13 of 27
September+0.20%+0.16%14 of 27
October−0.83%+0.32%14 of 27
November−0.60%+0.28%13 of 26
December+3.73%+4.19%18 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Charles River Laboratories International and its competitors

With 18,300 employees, Charles River Laboratories International, Inc. runs drug discovery, non-clinical development and safety testing services for pharmaceutical and biotechnology companies and for researchers. Its research models unit breeds and sells purpose-bred rats and mice, along with genetically engineered models, insourcing solutions, research animal diagnostics and cell therapy development. Its discovery and safety assessment unit tests novel drugs, oligonucleotides, biotherapeutics and antibodies through toxicology, pathology, bioanalysis and pharmacokinetics work, plus vivarium space.

Headquarters
Wilmington, United States
Employees
18,300
Founded
1947
Chief executive
Birgit Girshick
Charles River Laboratories International and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Charles River Laboratories InternationalCRL$16.19B14.3%367.4+107.53%
RevvityRVTY$17.84B16.3%70.5+62.50%
ICON PublicICLR$14.58B2.7%77.9+65.83%
Medpace HoldingsMEDP$19.12B21.4%38.0+54.32%
Guardant HealthGH$20.52B-39.4%—+54.06%
Quest DiagnosticsDGX$28.56B14.9%25.9+36.02%

Same industry or related industries, similar size. Compare Charles River Laboratories International with its competitors · Full profile